Table 2. Overall survival.

Analysis	Intervention	N	Median OS (months)	95% CI for median OS (months)	HR	95% CI for HR	P-value
AVOREN study (Escudier et al, 2008; Bracarda et al, 2007; Melichar et al, 2007; Escudier et al, 2007; Bajetta et al, 2008)
Interim	Bevacizumab plus IFN	327	Not reached	—	0.79	0.62–1.02	0.0670
	Placebo plus IFN	322	19.8	—	—	—	—
Sunitinib vs IFN phase III trial (Motzer et al, 2007b; Motzer et al, 2007c; Figlin et al, 2008; Motzer et al, 2007a; Motzer et al, 2006)
Second interim	Sunitinib	375	Not reached	—	0.65	0.45–0.94	0.02
	IFN	375	Not reached	—
Final	Sunitinib	375	26.4	23.9–32.9	0.821	0.673–1.001	0.051
	IFN	375	21.8	17.9–26.9
Censored finala	Sunitinib	375	26.4	23.0–32.9	0.808	0.661–0.987	0.0362
	IFN	375	20.0	17.8–26.9
Post hoc finalb	Sunitinib	193	28.1	19.5–NA	0.647	0.483–0.870	0.0033
	IFN	162	14.1	9.7–21.1

Abbreviations: CI=confidence interval; HR=hazard ratio; IFN=interferon; NA=not applicable; OS=overall survival.

^an=25 patients in the IFN group who crossed over to sunitinib.

^bIncludes only those patients who received no post-study treatment.